Bone and Cytokine Markers Associated With Bone Disease in Systemic Mastocytosis
The Journal of Allergy and Clinical Immunology: In Practice · 2023
DOI: 10.1016/j.jaip.2023.02.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2023. Verfasst von Tiago Azenha Rama und 12 weiteren Autor:innen. Beteiligte Einrichtung: Serviço de Imunoalergologia, Centro Hospitalar Universitário São João, Porto, Portugal; Serviço de Imunologia Básica e Clínica, Departamento de Patol…. Hauptthemen laut MEDLINE: Cytokines, Mastocytosis, Systemic, Bone Remodeling, Bone Resorption. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIBERONC, Ministerio de Ciencia, Innovación y Universidades, Instituto de Salud Carlos III.
Abstract (Originalsprache)
BACKGROUND: Mastocytosis encompasses a heterogeneous group of diseases characterized by tissue accumulation of clonal mast cells, which frequently includes bone involvement. Several cytokines have been shown to play a role in the pathogenesis of bone mass loss in systemic mastocytosis (SM), but their role in SM-associated osteosclerosis remains unknown. OBJECTIVE: To investigate the potential association between cytokine and bone remodeling markers with bone disease in SM, aiming at identifying biomarker profiles associated with bone loss and/or osteosclerosis. METHODS: A total of 120 adult patients with SM, divided into 3 age and sex-matched groups according to their bone status were studied: (1) healthy bone (n = 46), (2) significant bone loss (n = 47), and (3) diffuse bone sclerosis (n = 27). Plasma levels of cytokines and serum baseline tryptase and bone turnover marker levels were measured at diagnosis. RESULTS: Bone loss was associated with significantly higher levels of serum baseline tryptase (P = .01), IFN-γ (P = .05), IL-1β (P = .05), and IL-6 (P = .05) versus those found in patients with healthy bone. In contrast, patients with diffuse bone sclerosis showed significantly higher levels of serum baseline tryptase (P < .001), C-terminal telopeptide (P < .001), amino-terminal propeptide of type I procollagen (P < .001), osteocalcin (P < .001), bone alkaline phosphatase (P < .001), osteopontin (P < .01), and the C-C Motif Chemokine Ligand 5/RANTES chemokine (P = .01), together with lower IFN-γ (P = .03) and RANK-ligand (P = .04) plasma levels versus healthy bone cases. CONCLUSIONS: SM with bone mass loss is associated with a proinflammatory cytokine profile in plasma, whereas diffuse bone sclerosis shows increased serum/plasma levels of biomarkers related to bone formation and turnover, in association with an immunosuppressive cytokine secretion profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Serviço de Imunoalergologia, Centro Hospitalar Universitário São João, Porto, Portugal; Serviço de Imunologia Básica e Clínica, Departamento de Patologia, Faculdade de Medicina da Universidade do Porto, Porto, Portugal;…
- Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast) - Reference Center (CSUR) for Mastocytosis, Hospital Virgen del Valle, Complejo Hospitalario Universitario de Toledo, Toledo, Spain; Spanish Network o…
- Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain; DNA Sequencing Service (NUCLEUS), Instituto de Investigación Biomédica de Salamanca (IBSAL), University of Salamanca, Salamanca, Spain; Centro de Inve…
- Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain; Cancer Research Center (IBMCC, USAL-CSIC)…
- EPIUnit - Institute of Public Health, University of Porto, Porto, Portugal; Laboratory for Integrative and Translational Research in Population Health (ITR), Porto, Portugal.
Förderung
- CIBERONC
- Ministerio de Ciencia, Innovación y Universidades
- Instituto de Salud Carlos III
- European Regional Development Fund
- European Academy of Allergy and Clinical Immunology
Zitieren
APA
Rama, T. A., Henriques, A. F., Matito, A., Jara-Acevedo, M., Caldas, C., Mayado, A., Muñoz-González, J. I., Moreira, A., Cavaleiro-Rufo, J., García-Montero, A., Órfão, A., Sanchez-Muñoz, L., & Álvarez-Twose, I. (2023). Bone and Cytokine Markers Associated With Bone Disease in Systemic Mastocytosis. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2023.02.007
Vancouver
Rama TA, Henriques AF, Matito A, Jara-Acevedo M, Caldas C, Mayado A, et al. Bone and Cytokine Markers Associated With Bone Disease in Systemic Mastocytosis. The Journal of Allergy and Clinical Immunology: In Practice. 2023. doi:10.1016/j.jaip.2023.02.007
BibTeX
@article{Rama2023,
author = {Rama, Tiago Azenha and Henriques, Ana Filipa and Matito, Almudena and Jara-Acevedo, Maria and Caldas, Carolina and Mayado, Andrea and Muñoz-González, Javier I and Moreira, André and Cavaleiro-Rufo, João and García-Montero, Andrés and Órfão, Alberto and Sanchez-Muñoz, Laura and Álvarez-Twose, Iván},
title = {Bone and Cytokine Markers Associated With Bone Disease in Systemic Mastocytosis},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2023},
doi = {10.1016/j.jaip.2023.02.007}
}
EUVIMED